Spectral Medical Inc.

EDT.TO on TSXToday's ChangeVolume52 Week Range (Low/Hi)Market Cap
1.08CAN 0.04/3.85%196,0630.26 / 1.18194.14M
EDTXF on OTCQXToday's ChangeVolume52 Week Range (Low/Hi)Market Cap
0.87US 0.02/2.32%33,4700.2250 / 0.9650166.73M

Contact Information

Spectral Medical Inc.

Headquarters:
Finance 135 - 2 The West Mall,
Toronto, Ontario
M9C 1C2, Canada
Email: Send a message
Website: Visit website
For more information...
Lead: Barry Mire
Second: Mariam Ghoneim

Spectral is a Phase III company seeking U.S. FDA approval for its lead theranostics product for the treatment of severe sepsis with septic shock. PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream. Directed by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis, Spectral's EUPHRATES trial is the world's only active and most innovative Phase III study in the area of septic shock.

PMX has been approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more than 100,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. Approximately 350,000 patients are diagnosed with severe sepsis and septic shock in North America each year, representing a greater than $2 billion market opportunity for Spectral.

Spectral is listed on the Toronto Stock Exchange under the symbol SDI, and on the OTCQX under the symbol DIAGF. For more information please visit www.spectraldx.com

Paul Walker, M.D., Ph.D., F.R.C.S.C - Director, President & Chief Executive Officer

Tony Businskas, B.A., C.A. - Chief Financial Officer

Debra M. Foster RN, B.Sc. (Human Biology) - Vice President, Clinical Development

Dr. Gualtiero Guadagni, Ph.D - Vice President, Sales and Marketing

Anthony Bihl - Chairman of the Board

Paul Walker - Director

Kevin Giese - Director

Guillermo Herrera - Director

Koichiro Takeshita - Director

William Stevens - Director

Stock Information

EDT.TO on TSX
1.08CAN
Today's Change
0.04/3.85%
Volume
196,063
EDTXF on OTCQX
0.87US
Today's Change
0.02/2.32%
Volume
33,470

Company Overview

Spectral is a Phase III company seeking U.S. FDA approval for its lead theranostics product for the treatment of severe sepsis with septic shock. PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream. Directed by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis, Spectral's EUPHRATES trial is the world's only active and most innovative Phase III study in the area of septic shock.

PMX has been approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more than 100,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. Approximately 350,000 patients are diagnosed with severe sepsis and septic shock in North America each year, representing a greater than $2 billion market opportunity for Spectral.

Spectral is listed on the Toronto Stock Exchange under the symbol SDI, and on the OTCQX under the symbol DIAGF. For more information please visit www.spectraldx.com

Management

Paul Walker, M.D., Ph.D., F.R.C.S.C - Director, President & Chief Executive Officer

Tony Businskas, B.A., C.A. - Chief Financial Officer

Debra M. Foster RN, B.Sc. (Human Biology) - Vice President, Clinical Development

Dr. Gualtiero Guadagni, Ph.D - Vice President, Sales and Marketing

Board of Directors

Anthony Bihl - Chairman of the Board

Paul Walker - Director

Kevin Giese - Director

Guillermo Herrera - Director

Koichiro Takeshita - Director

William Stevens - Director

Contact Information

Headquarters:
Finance 135 - 2 The West Mall,
Toronto, Ontario
M9C 1C2, Canada
Email: Send a message
Website: Visit website